Compare Inovio Pharmaceuticals Inc (INO) vs Workiva Inc (WK) Price & Performance

INO trades at $0.9001, up 17.54% in the last session, but the technical outlook is bearish with key indicators like the 6-day RSI at 73.22 signaling overbought conditions. Fundamentally, the company reports minimal revenue of $65,340 in 2025 against a net loss of $84.95 million, reflecting a net income margin of -130,000%. Recent news highlights FDA review progress for INO-3107, with a PDUFA date set for October 30, 2026, representing a critical near-term catalyst.

The investment case hinges on the binary FDA decision for INO-3107, with a consensus price target of $3.25 implying significant upside if approved. However, high cash burn, persistent losses, and a bearish technical setup present substantial risks. Analyst sentiment is mixed with a 52.95% buy rating, but the stock remains a high-risk, event-driven play.

WK trades at $68.07, down 1.42% today, with strong analyst consensus (16 Buy, 2 Hold) and a $69.00 price target. Recent Q2 2026 earnings beat expectations with $0.77 EPS, driven by 19% revenue growth. Technicals show bullish moving averages but overbought RSI levels, while fundamentals highlight robust gross margins of 80.21% and improving profitability trends into 2026.

Outlook remains positive given earnings momentum and AI product launches, though high P/E of 81.04 poses valuation risk. Key risks include competitive pressures and reliance on subscription growth execution. Institutional accumulation by firms like Assenagon Asset Management supports bullish sentiment.